 The FDA has approved a new Alzheimer's treatment from Eli Lilly aimed at slowing the decline in patients at early stages of the disease. Alexander Tin has more. The FDA has now approved a new Alzheimer's treatment called Denanamab. It looks to be effective at slowing the decline of patients at early stages of the disease after as little as six months of infusions from the drug.